{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T10:39:09Z","timestamp":1782297549841,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Significant comorbidities, advanced age, and a poor performance status prevent surgery and systemic treatment for many patients with localized (non-metastatic) pancreatic ductal adenocarcinoma (PDAC). These patients are currently treated with \u2018best supportive care\u2019. Therefore, it is desirable to find a treatment option which could improve both disease control and quality of life in these patients. A brief course of high-dose high-precision radiotherapy i.e. stereotactic ablative body radiotherapy (SABR) may be feasible.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A nationwide multicenter trial performed within a previously established large prospective cohort (the Dutch Pancreatic cancer project; PACAP) according to the \u2018Trial within cohorts\u2019 (TwiCs) design. Patients enrolled in the PACAP cohort routinely provide informed consent to answer quality of life questionnaires and to be randomized according to the TwiCs design when eligible for a study. Patients with localized PDAC who are unfit for chemotherapy and surgery or those who refrain from these treatments are eligible. Patients will be randomized between SABR (5 fractions of 8\u2009Gy) with \u2018best supportive care\u2019 and \u2018best supportive care\u2019 only. The primary endpoint is overall survival from randomization. Secondary endpoints include preservation of quality of life (EORTC-QLQ-C30 and -PAN26), NRS pain score response and WHO performance scores at baseline, and, 3, 6 and 12\u2009months. Acute and late toxicity will be scored using CTCAE criteria version 5.0: assessed at baseline, day of last fraction, at 3 and 6\u2009weeks, and 3, 6 and 12\u2009months following SABR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The PANCOSAR trial studies the added value of SBRT as compared to \u2018best supportive care\u2019 in patients with localized PDAC who are medically unfit to receive chemotherapy and surgery, or refrain from these treatments. This study will assess whether SABR, in comparison to best supportive care, can relieve or delay tumor-related symptoms, enhance quality of life, and extend survival in these patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical trials, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05265663\">NCT05265663<\/jats:ext-link>, Registered March 3 2022, Retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10419-4","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T23:02:56Z","timestamp":1672354976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design"],"prefix":"10.1186","volume":"22","author":[{"given":"D.","family":"Doppenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H. J.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P. W.","family":"Intven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Groot","family":"Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kazemier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Q.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. M. E.","family":"Nuyttens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"van Os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. C.","family":"van Santvoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"van Tienhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Verkooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Versteijne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Wilmink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"Lagerwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-8920","authenticated-orcid":false,"given":"A. M. E.","family":"Bruynzeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Dutch Pancreatic Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"issue":"10242","key":"10419_CR1","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(20)30974-0.","journal-title":"Lancet"},{"issue":"9791","key":"10419_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","volume":"378","author":"A Vincent","year":"2011","unstructured":"Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(10)62307-0.","journal-title":"Lancet."},{"issue":"Suppl 5","key":"10419_CR3","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"26","author":"M Ducreux","year":"2015","unstructured":"Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56\u201368. https:\/\/doi.org\/10.1093\/annonc\/mdv295.","journal-title":"Ann Oncol"},{"issue":"9","key":"10419_CR4","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/0284186X.2018.1470330","volume":"57","author":"M Zijlstra","year":"2018","unstructured":"Zijlstra M, van der Geest LGM, van Laarhoven HWM, Lemmens V, van de Poll-Franse LV, Raijmakers NJH. Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands. Acta Oncol. 2018;57(9):1185\u201391. https:\/\/doi.org\/10.1080\/0284186X.2018.1470330.","journal-title":"Acta Oncol"},{"issue":"16","key":"10419_CR5","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2014.59.7930","volume":"33","author":"GM Heestand","year":"2015","unstructured":"Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33(16):1770\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.59.7930.","journal-title":"J Clin Oncol"},{"issue":"1","key":"10419_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12876-018-0777-z","volume":"18","author":"L Zhang","year":"2018","unstructured":"Zhang L, Xiu D, Yuan C, Jiang B, Ma Z. Pancreatic duct obstruction after pancreaticojejunostomy: implications for early prediction and prevention of long-term pancreatic complications. BMC Gastroenterol. 2018;18(1):53. https:\/\/doi.org\/10.1186\/s12876-018-0777-z.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"10419_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3748\/wjg.v28.i7.745","volume":"28","author":"T Ermongkonchai","year":"2022","unstructured":"Ermongkonchai T, Khor R, Muralidharan V, et al. Stereotactic radiotherapy and the potential role of magnetic resonance-guided adaptive techniques for pancreatic cancer. World J Gastroenterol. 2022;28(7):745\u201354. https:\/\/doi.org\/10.3748\/wjg.v28.i7.745.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10419_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/PPO.0000000000000292","volume":"23","author":"CH Crane","year":"2017","unstructured":"Crane CH, O'Reilly EM. Ablative radiotherapy doses for locally advanced: pancreatic Cancer (LAPC). Cancer J. 2017;23(6):350\u20134. https:\/\/doi.org\/10.1097\/PPO.0000000000000292.","journal-title":"Cancer J"},{"issue":"21","key":"10419_CR9","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.30856","volume":"123","author":"SWL de Geus","year":"2017","unstructured":"de Geus SWL, Eskander MF, Kasumova GG, et al. Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer. 2017;123(21):4158\u201367. https:\/\/doi.org\/10.1002\/cncr.30856.","journal-title":"Cancer."},{"key":"10419_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ctro.2019.04.020","volume":"18","author":"AME Bruynzeel","year":"2019","unstructured":"Bruynzeel AME, Lagerwaard FJ. The role of biological dose-escalation for pancreatic cancer. Clin Transl Radiat Oncol. 2019;18:128\u201330. https:\/\/doi.org\/10.1016\/j.ctro.2019.04.020.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"2","key":"10419_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","volume":"97","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Int J Radiat Oncol Biol Phys. 2017;97(2):313\u201322. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.10.030.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10419_CR12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1748-717X-8-240","volume":"8","author":"CH Kim","year":"2013","unstructured":"Kim CH, Ling DC, Wegner RE, et al. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiat Oncol. 2013;8:240. https:\/\/doi.org\/10.1186\/1748-717X-8-240.","journal-title":"Radiat Oncol"},{"issue":"1","key":"10419_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/COC.0000000000000090","volume":"40","author":"RL Yechieli","year":"2017","unstructured":"Yechieli RL, Robbins JR, Mahan M, Siddiqui F, Ajlouni M. Stereotactic body radiotherapy for elderly patients with medically inoperable pancreatic Cancer. Am J Clin Oncol. 2017;40(1):22\u20136. https:\/\/doi.org\/10.1097\/COC.0000000000000090.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10419_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1245\/s10434-017-6134-6","volume":"25","author":"JF Ryan","year":"2018","unstructured":"Ryan JF, Groot VP, Rosati LM, et al. Stereotactic body radiation therapy for isolated local recurrence after surgical resection of pancreatic ductal adenocarcinoma appears to be safe and effective. Ann Surg Oncol. 2018;25(1):280\u20139. https:\/\/doi.org\/10.1245\/s10434-017-6134-6.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10419_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ije\/dyw050","volume":"46","author":"JM van der Velden","year":"2017","unstructured":"van der Velden JM, Verkooijen HM, Young-Afat DA, et al. The cohort multiple randomized controlled trial design: a valid and efficient alternative to pragmatic trials? Int J Epidemiol. 2017;46(1):96\u2013102. https:\/\/doi.org\/10.1093\/ije\/dyw050.","journal-title":"Int J Epidemiol"},{"issue":"17","key":"10419_CR16","first-page":"A5762","volume":"157","author":"HM Verkooijen","year":"2013","unstructured":"Verkooijen HM, Roes K, van Gils CH. Cohort multiple randomized controlled trial: a solution for the evaluation of multiple interventions. Ned Tijdschr Geneeskd. 2013;157(17):A5762 \u2018Cohort multiple randomized controlled trial\u2019: een oplossing voor de evaluatie van multipele interventies.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"4","key":"10419_CR17","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1097\/SLA.0000000000003779","volume":"271","author":"M Strijker","year":"2020","unstructured":"Strijker M, Mackay TM, Bonsing BA, et al. Establishing and coordinating a Nationwide multidisciplinary study group: lessons learned by the Dutch pancreatic Cancer group. Ann Surg. 2020;271(4):e102\u20134. https:\/\/doi.org\/10.1097\/SLA.0000000000003779.","journal-title":"Ann Surg"},{"issue":"2","key":"10419_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/0284186X.2017.1346381","volume":"57","author":"C van den Braak RRJ","year":"2018","unstructured":"van den Braak RRJ C, van Rijssen LB, van Kleef JJ, et al. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncol. 2018;57(2):195\u2013202. https:\/\/doi.org\/10.1080\/0284186X.2017.1346381.","journal-title":"Acta Oncol"},{"issue":"10","key":"10419_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.hpb.2017.06.010","volume":"19","author":"LB van Rijssen","year":"2017","unstructured":"van Rijssen LB, Koerkamp BG, Zwart MJ, et al. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch pancreatic Cancer audit. HPB (Oxford). 2017;19(10):919\u201326. https:\/\/doi.org\/10.1016\/j.hpb.2017.06.010.","journal-title":"HPB (Oxford)"},{"issue":"4","key":"10419_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/MPA.0000000000001018","volume":"47","author":"M Strijker","year":"2018","unstructured":"Strijker M, Gerritsen A, van Hilst J, et al. The Dutch pancreas biobank within the Parelsnoer institute: a Nationwide biobank of pancreatic and Periampullary diseases. Pancreas. 2018;47(4):495\u2013501. https:\/\/doi.org\/10.1097\/MPA.0000000000001018.","journal-title":"Pancreas."},{"issue":"3","key":"10419_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/EDE.0000000000000435","volume":"27","author":"DA Young-Afat","year":"2016","unstructured":"Young-Afat DA, Verkooijen HA, van Gils CH, et al. Brief report: staged-informed consent in the cohort multiple randomized controlled trial design. Epidemiology. 2016;27(3):389\u201392. https:\/\/doi.org\/10.1097\/EDE.0000000000000435.","journal-title":"Epidemiology."},{"key":"10419_CR22","unstructured":"Common Terminology Criteria for Adverse Events. Version 5.0. Published November 27, 2017\u00a0US Department of Health and Human Services - 2020."},{"key":"10419_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13063-015-0586-4","volume":"16","author":"JP Burbach","year":"2015","unstructured":"Burbach JP, Verkooijen HM, Intven M, et al. RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Trials. 2015;16:58. https:\/\/doi.org\/10.1186\/s13063-015-0586-4.","journal-title":"Trials"},{"issue":"1","key":"10419_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11912-020-01000-y","volume":"23","author":"A Dohm","year":"2021","unstructured":"Dohm A, Diaz R, Nanda RH. The role of radiation therapy in the older patient. Curr Oncol Rep. 2021;23(1):11. https:\/\/doi.org\/10.1007\/s11912-020-01000-y.","journal-title":"Curr Oncol Rep"},{"key":"10419_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jclinepi.2019.12.015","volume":"120","author":"AM Couwenberg","year":"2020","unstructured":"Couwenberg AM, Burbach JPM, May AM, Berbee M, Intven MPW, Verkooijen HM. The trials within cohorts design facilitated efficient patient enrollment and generalizability in oncology setting. J Clin Epidemiol. 2020;120:33\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.12.015.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10419_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.surg.2005.08.014","volume":"139","author":"NS Abraham","year":"2006","unstructured":"Abraham NS, Young JM, Solomon MJ. A systematic review of reasons for nonentry of eligible patients into surgical randomized controlled trials. Surgery. 2006;139(4):469\u201383. https:\/\/doi.org\/10.1016\/j.surg.2005.08.014.","journal-title":"Surgery."},{"issue":"9","key":"10419_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jama.293.9.1089","volume":"293","author":"M King","year":"2005","unstructured":"King M, Nazareth I, Lampe F, et al. Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA. 2005;293(9):1089\u201399. https:\/\/doi.org\/10.1001\/jama.293.9.1089.","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1186\/s12885-023-10521-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10419-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10419-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T01:08:23Z","timestamp":1674263303000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10419-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10419"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10419-4","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12885-023-10521-1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12885-023-10521-1","URL":"https:\/\/doi.org\/10.1186\/s12885-023-10521-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Medical Ethics Review board of VU University Medical Center in Amsterdam approved execution of the research protocol on july 17 2020.Research institute: Cancer Center AmsterdamReference number: 2020.085 - NL72181.029.20Ethical approval PANCOSAR study (includes English IRB approval).All patients included in the PANCOSAR-study have provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1363"}}